OBI Pharma, Inc. (TPEX: 4174)
Taiwan
· Delayed Price · Currency is TWD 63.60
+0.20 (0.32%)
Nov 21, 2024, 1:30 PM CST
OBI Pharma Company Description
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally.
It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs.
The company was founded in 2002 and is headquartered in Taipei, Taiwan.
OBI Pharma, Inc.
| Country | Taiwan |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Heidi Wang |
Contact Details
Address: No. 508, Sec. 7 Taipei, 115 Taiwan | |
| Phone | 886 2 2786 6589 |
| Website | obipharma.com |
Stock Details
| Ticker Symbol | 4174 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004174008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Heidi Wang Ph.D. | Chief Executive Officer |
| Dr. Ming-Tain Lai | Chief Scientific Officer |
| Colin Kao | Chief Financial Officer, Accounting Supervisor and Corporate Governance Supervisor |
| Po-Jen Chang | Director of Human Resources and Administration |
| Sharon Lee | Director of Public Affairs |
| Kevin P. Poulos | Chief Business Officer of OBI Pharma USA, Inc. |
| Dr. Wayne Saville M.D. | Chief Medical Officer of OBI Pharma USA, Inc. |
| Dr. Dong Xu Ph.D. | Senior Vice President of Biostatistics and Data Management of OBI Pharma USA, Inc. |
| Chun-Hung Chou | Vice President of Chemical Pharmacy and Research & Development Office |